93 related articles for article (PubMed ID: 7657282)
1. p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: correlation with tumor grade and survival.
Diamantis I; Karamitopoulou E; Perentes E; Zimmermann A
Hepatology; 1995 Sep; 22(3):774-9. PubMed ID: 7657282
[TBL] [Abstract][Full Text] [Related]
2. Expression of the GLUT1 glucose transporter and p53 in carcinomas of the pancreatobiliary tract.
Sung JY; Kim GY; Lim SJ; Park YK; Kim YW
Pathol Res Pract; 2010 Jan; 206(1):24-9. PubMed ID: 19819644
[TBL] [Abstract][Full Text] [Related]
3. An immunohistochemical study of p53 protein in gallbladder and extrahepatic bile duct/ampullary carcinomas.
Teh M; Wee A; Raju GC
Cancer; 1994 Sep; 74(5):1542-5. PubMed ID: 7520348
[TBL] [Abstract][Full Text] [Related]
4. Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts.
Argani P; Shaukat A; Kaushal M; Wilentz RE; Su GH; Sohn TA; Yeo CJ; Cameron JL; Kern SE; Hruban RH
Cancer; 2001 Apr; 91(7):1332-41. PubMed ID: 11283934
[TBL] [Abstract][Full Text] [Related]
5. Expression and clinical significance of cell cycle regulatory proteins in gallbladder and extrahepatic bile duct cancer.
Kim WB; Han HJ; Lee HJ; Park SS; Song TJ; Kim HK; Suh SO; Kim YC; Choi SY
Ann Surg Oncol; 2009 Jan; 16(1):23-34. PubMed ID: 18979138
[TBL] [Abstract][Full Text] [Related]
6. Carcinoma of the ampulla of Vater associated with or without adenoma: a clinicopathologic analysis of 198 cases with reference to p53 and Ki-67 immunohistochemical expressions.
Takashima M; Ueki T; Nagai E; Yao T; Yamaguchi K; Tanaka M; Tsuneyoshi M
Mod Pathol; 2000 Dec; 13(12):1300-7. PubMed ID: 11144926
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of Ki-67 and p53 antigen expression in carcinomas of bile duct and gallbladder.
Shrestha ML; Miyake H; Kikutsuji T; Tashiro S
J Med Invest; 1998 Aug; 45(1-4):95-102. PubMed ID: 9864969
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the expression of p53, MIB-1 (Ki-67 antigen), and argyrophilic nucleolar organizer regions in carcinoma of the extrahepatic bile duct.
Suto T; Sugai T; Nakamura S; Funato O; Nitta H; Sasaki R; Kanno S; Saito K
Cancer; 1998 Jan; 82(1):86-95. PubMed ID: 9428483
[TBL] [Abstract][Full Text] [Related]
9. Lack of CD44 variant 6 expression in advanced extrahepatic bile duct/ampullary carcinoma.
Yokoyama Y; Hiyama E; Murakami Y; Matsuura Y; Yokoyama T
Cancer; 1999 Nov; 86(9):1691-9. PubMed ID: 10547541
[TBL] [Abstract][Full Text] [Related]
10. p53 protein immunoreactivity in cancers of the gallbladder, extrahepatic bile ducts and ampulla of Vater.
Lee CS; Pirdas A
Pathology; 1995 Apr; 27(2):117-20. PubMed ID: 7567135
[TBL] [Abstract][Full Text] [Related]
11. Neoplasia of the ampulla of Vater. Ki-ras and p53 mutations.
Scarpa A; Capelli P; Zamboni G; Oda T; Mukai K; Bonetti F; Martignoni G; Iacono C; Serio G; Hirohashi S
Am J Pathol; 1993 Apr; 142(4):1163-72. PubMed ID: 8475992
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers.
Chuang SC; Lee KT; Tsai KB; Sheen PC; Nagai E; Mizumoto K; Tanaka M
World J Surg; 2004 Oct; 28(10):995-1000. PubMed ID: 15573254
[TBL] [Abstract][Full Text] [Related]
13. nm23-H1 protein immunoreactivity in cancers of the gallbladder, extrahepatic bile ducts and ampulla of Vater.
Lee CS; Pirdas-Zivcic A
Pathology; 1994 Oct; 26(4):448-52. PubMed ID: 7892048
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of cell cycle- and apoptosis-related markers in biliary tract cancer: a tissue microarray-based approach revealing a distinctive immunophenotype for intrahepatic and extrahepatic cholangiocarcinomas.
Karamitopoulou E; Tornillo L; Zlobec I; Cioccari L; Carafa V; Borner M; Schaffner T; Brunner T; Diamantis I; Zimmermann A; Terracciano L
Am J Clin Pathol; 2008 Nov; 130(5):780-6. PubMed ID: 18854271
[TBL] [Abstract][Full Text] [Related]
15. Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma.
Nasif WA; El-Emshaty HM; Tabll A; Elmasry SA; Attallah AM; Gad Elhak NA
Hepatogastroenterology; 2004; 51(58):1001-6. PubMed ID: 15239234
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of N-myristoyltransferase in gallbladder carcinomas.
Rajala RV; Radhi JM; Kakkar R; Datla RS; Sharma RK
Cancer; 2000 May; 88(9):1992-9. PubMed ID: 10813869
[TBL] [Abstract][Full Text] [Related]
17. Ras p21 protein immunoreactivity and its relationship to p53 expression and prognosis in gallbladder and extrahepatic biliary carcinoma.
Lee CS
Eur J Surg Oncol; 1997 Jun; 23(3):233-7. PubMed ID: 9236898
[TBL] [Abstract][Full Text] [Related]
18. The value of p53 protein expression in gallbladder carcinoma: analysis of 60 cases.
da Rocha AO; Coutinho LM; Scholl JG; Leboutte LD
Hepatogastroenterology; 2004; 51(59):1310-4. PubMed ID: 15362740
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical study of microvessel density, CD44 (standard form), p53 protein and c-erbB2 in gallbladder carcinoma.
Kalekou H; Miliaras D
J Gastroenterol Hepatol; 2004 Jul; 19(7):812-8. PubMed ID: 15209630
[TBL] [Abstract][Full Text] [Related]
20. p53 protein accumulation in tumors of the ampulla of Vater.
Younes M; Riley S; Genta RM; Mosharaf M; Mody DR
Cancer; 1995 Oct; 76(7):1150-4. PubMed ID: 8630891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
